Oncology Xagena
An investigational new drug Sutent ( Sunitinib ) more than doubled survival and significantly reduced tumor growth and spread in patients with Imatinib-resistant gastrointestinal stromal tumors ( GIS ...
Axel Ullrich, at the Max Planck Institute of Biochemistry in Martinsried, Germany, already showed at the beginning of the 1990s that blocking blood vessel development in a tumour slows down its growth ...
A phase III clinical trial has shown that Lapatinib ( Tykerb ) slows cancer growth and improves survival in a subset of patients with an advanced renal cell carcinoma ( RCC ) that continued to grow de ...
A phase II study is assessing the safety and efficacy of Sunitinib ( Sutent ) in patients with advanced non-small cell lung cancer ( NSCLC ) that had progressed following standard therapy. This ...
A study suggests that Sunitinib ( Sutent ) is a promising agent for treatment of metastatic renal cell cancer, currently a disease without highly effective treatment options. The study is published ...
Sunitinib ( Sutent ) is more effective than the current standard cytokine treatment given as an initial therapy for patients with advanced kidney cancer, also known as metastatic renal cell carcinoma ...
A small pilot study from researchers at Dana-Farber Cancer Institute has shown that children with a rare digestive-tract cancer that is resistant to front-line therapy may benefit from a newer targete ...
Treatment with Everolimus ( Afinitor ) prolongs progression-free survival relative to placebo in patients with metastatic renal cell carcinoma who have experienced treatment failure on other regimens. ...
Genetic variations ensure that no two people are exactly alike, nor are their cancers. Researchers now have the tools and the knowledge to predict how individuals will respond to cancer therapy, ena ...
Treatment with Everolimus ( Certican ) prolongs progression-free survival relative to placebo in patients with metastatic kidney cancer ( renal cell carcinoma ) who have experienced treatment failur ...
Treatment with Everolimus ( Afinitor ) prolongs progression-free survival relative to placebo in patients with metastatic renal cell carcinoma who have experienced treatment failure on other regimens. ...
Sunitinib ( Sutent ) prolongs progression-free and overall survival, and is safe and well tolerated in advanced kidney cancer ( metastatic renal cell carcinoma ) patients with a poor prognosis such as ...
The safety and maximum tolerated dose ( MTD ) of Sunitinib malate( Sutent ) in combination with Bevacizumab ( Avastin ) has been assessed in patients with metastatic renal cell carcinoma ( mRCC ) in a ...
Until now, only Imatinib ( Gleevec, Glivec ) and Sunitinib ( Sutent ) have proven clinical benefit in patients with gastrointestinal stromal tumours ( GIST ), but almost all metastatic GIST eventually ...
Pazopanib ( Votrient ) and Sunitinib ( Sutent ) provided a progression-free survival benefit, as compared with placebo or Interferon, in previous phase 3 studies involving patients with metastatic ren ...
